C K Brierley1,2,3, J Staves1, C Roberts4, H Johnson5, P Vyas1,2,3, L T Goodnough6, M F Murphy1,3,7. 1. Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom. 2. MRC Molecular Haematology Unit, University of Oxford, Oxford, United Kingdom. 3. NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom. 4. Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom. 5. Oncology Clinical Trials Office (OCTO), Department of Oncology, University of Oxford, Oxford, United Kingdom. 6. Departments of Pathology and Medicine, Stanford University, Stanford, California. 7. National Health Service Blood and Transplant, Oxford, United Kingdom.
Abstract
BACKGROUND: CD47 is a novel therapeutic target in the treatment of solid-organ and hematologic malignancies. CD47 is also expressed on RBCs. Here, we report our experience of the RBC effects and the impact on blood bank testing and transfusion management in a Phase 1 trial of the humanized anti-CD47 monoclonal antibody Hu5F9-G4 in relapsed or primary refractory acute myeloid leukemia (AML) (NCT02678338). STUDY DESIGN AND METHODS: Nineteen patients with relapsed or primary refractory AML treated across five UK centers were included for analysis. Patients received escalating doses of Hu5F9-G4. Serial laboratory data were collected to evaluate impact on hemoglobin (Hb), markers of hemolysis (bilirubin, lactate dehydrogenase, reticulocyte count), transfusion requirements, and blood compatibility testing. RESULTS: A decline in Hb was observed with drug administration (median Hb change, -1.0 g/dL; range, 0.4-1.6) with associated increase in transfusion requirements. Patients responded to transfusion with a median Hb increment per unit of 1.0 g/dL. RBC agglutination was seen in all cases without associated change in Hb, lactate dehydrogenase, bilirubin, or reticulocyte count. Nine of 19 (47%) patients developed a newly positive antibody screen with a pan-agglutinin identified in plasma. Invalid ABO blood grouping occurred in 4 of 12 (33%) non-group O patients due to anomalous reactivity in the reverse ABO-type results. CONCLUSIONS: Treatment with Hu5F9-G4 in patients with AML resulted in an Hb decline and increased transfusion requirements. Problems with ABO blood typing and compatibility testing were widely observed and should be expected by centers treating recipients of Hu5F9-G4.
BACKGROUND:CD47 is a novel therapeutic target in the treatment of solid-organ and hematologic malignancies. CD47 is also expressed on RBCs. Here, we report our experience of the RBC effects and the impact on blood bank testing and transfusion management in a Phase 1 trial of the humanized anti-CD47 monoclonal antibody Hu5F9-G4 in relapsed or primary refractory acute myeloid leukemia (AML) (NCT02678338). STUDY DESIGN AND METHODS: Nineteen patients with relapsed or primary refractory AML treated across five UK centers were included for analysis. Patients received escalating doses of Hu5F9-G4. Serial laboratory data were collected to evaluate impact on hemoglobin (Hb), markers of hemolysis (bilirubin, lactate dehydrogenase, reticulocyte count), transfusion requirements, and blood compatibility testing. RESULTS: A decline in Hb was observed with drug administration (median Hb change, -1.0 g/dL; range, 0.4-1.6) with associated increase in transfusion requirements. Patients responded to transfusion with a median Hb increment per unit of 1.0 g/dL. RBC agglutination was seen in all cases without associated change in Hb, lactate dehydrogenase, bilirubin, or reticulocyte count. Nine of 19 (47%) patients developed a newly positive antibody screen with a pan-agglutinin identified in plasma. Invalid ABO blood grouping occurred in 4 of 12 (33%) non-group O patients due to anomalous reactivity in the reverse ABO-type results. CONCLUSIONS: Treatment with Hu5F9-G4 in patients with AML resulted in an Hb decline and increased transfusion requirements. Problems with ABO blood typing and compatibility testing were widely observed and should be expected by centers treating recipients of Hu5F9-G4.
Authors: Khatora S Opperman; Kate Vandyke; Peter J Psaltis; Jacqueline E Noll; Andrew C W Zannettino Journal: Cancer Metastasis Rev Date: 2021-01-06 Impact factor: 9.264
Authors: Gabriela Andrejeva; Benjamin J Capoccia; Ronald R Hiebsch; Michael J Donio; Isra M Darwech; Robyn J Puro; Daniel S Pereira Journal: J Immunol Date: 2021-01-11 Impact factor: 5.422
Authors: Amer M Zeidan; Daniel J DeAngelo; Jeanne Palmer; Christopher S Seet; Martin S Tallman; Xin Wei; Heather Raymon; Priya Sriraman; Stephan Kopytek; Jan Philipp Bewersdorf; Michael R Burgess; Kristen Hege; Wendy Stock Journal: Ann Hematol Date: 2022-01-04 Impact factor: 4.030